

BYDUREON BCISE - (2MG/0.85ML ; SUSPENSION,EXTENDED RELEASE)

Generic Name	EXENATIDE SYNTHETIC	Innovator	Astrazeneca
Dosage	2MG/0.85ML ; SUSPENSION,EXTENDED RELEASE	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	BYDUREON BCISE is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.